Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and ...

Feedback from front-line clinicians about the benefits of AI ambient listening tools typically solicits the same confident ...

Ajertil, A., Jirari Rim, M’Benga. L.-J.K. and El Quessar, A. (2025) Severe and Rare Cerebrovascular Involvement in Systemic Lupus Erythematosus: Case Report and Literature Review. Open Access Library ...

New findings highlight Telomir-1’s impact on CASP8 and GSTP1, two critical genes that regulate cell death and glutathione-based detoxification pathways often disrupted in cancer. MIAMI, FLORIDA / ...

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine ...

Postgraduate medical education (PGME) is the critical bridge between medical school and independent practice. In the UK and globally, this training has undergone incremental change over the past ...

Foluso Agboola discusses the Institute for Clinical and Economic Review's newest analysis, which has found that most new ...

Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of ...

Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced positive topline ...

Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a ...

Ozekibart meets its primary endpoint in chondrosarcoma, demonstrating a statistically significant and clinically meaningful improvement in median progression-free ...